Chemed's stock experienced a significant pre-market plunge, dropping 14.49% on Thursday. The sharp decline occurred ahead of the regular trading session, indicating negative investor sentiment.

The sell-off appears to be driven by Jefferies' decision to cut its price target for Chemed from $475 to $400. Analyst target price reductions often signal concerns about a company's future prospects and can trigger immediate market reactions as investors reassess valuation expectations.